Integra LifeSciences Holdings Corporation (IL3.F)
- Previous Close
12.20 - Open
12.00 - Bid 11.90 x --
- Ask 12.00 x --
- Day's Range
12.00 - 12.00 - 52 Week Range
10.90 - 29.20 - Volume
57 - Avg. Volume
5 - Market Cap (intraday)
932.548M - Beta (5Y Monthly) 1.27
- PE Ratio (TTM)
-- - EPS (TTM)
-0.34 - Earnings Date Jul 28, 2025 - Aug 1, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Integra LifeSciences Holdings Corporation manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company addresses the needs of plastic, and reconstructive and general surgeons focused on the treatment of acute wounds, such as burns and chronic wounds, including diabetic foot ulcers; and provides surgical tissue repair products for hernia, tendon, peripheral nerve repair, and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. Further, it is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
www.integralife.comRecent News: IL3.F
View MorePerformance Overview: IL3.F
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IL3.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IL3.F
View MoreValuation Measures
Market Cap
946.19M
Enterprise Value
2.52B
Trailing P/E
--
Forward P/E
5.74
PEG Ratio (5yr expected)
0.72
Price/Sales (ttm)
0.64
Price/Book (mrq)
0.69
Enterprise Value/Revenue
1.72
Enterprise Value/EBITDA
15.51
Financial Highlights
Profitability and Income Statement
Profit Margin
-1.78%
Return on Assets (ttm)
2.66%
Return on Equity (ttm)
-1.86%
Revenue (ttm)
1.62B
Net Income Avi to Common (ttm)
-28.96M
Diluted EPS (ttm)
-0.34
Balance Sheet and Cash Flow
Total Cash (mrq)
273.3M
Total Debt/Equity (mrq)
132.59%
Levered Free Cash Flow (ttm)
35.55M